News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bausch & Lomb (BOL) Teams With Novartis Ophthalmics AG (NVS) To Co-Promote Bausch & Lomb Retisert(TM)



2/9/2006 1:08:29 PM

ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 9, 2006--Bausch & Lomb (NYSE:BOL) and Novartis Ophthalmics, a business unit of Novartis Pharmaceutical Corp. (NYSE: NVS), will co-promote Bausch & Lomb's patented orphan drug Retisert(TM) (fluocinolone acetonide intravitreal implant) 0.59 mg, in the United States. Retisert is indicated for the treatment of chronic noninfectious posterior segment uveitis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES